[go: up one dir, main page]

WO2021166984A1 - Procédé de fabrication d'un systèmes de cellules nerveuses comprenant des cellules nerveuses myélinisées - Google Patents

Procédé de fabrication d'un systèmes de cellules nerveuses comprenant des cellules nerveuses myélinisées Download PDF

Info

Publication number
WO2021166984A1
WO2021166984A1 PCT/JP2021/006037 JP2021006037W WO2021166984A1 WO 2021166984 A1 WO2021166984 A1 WO 2021166984A1 JP 2021006037 W JP2021006037 W JP 2021006037W WO 2021166984 A1 WO2021166984 A1 WO 2021166984A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
nerve
schwann
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/006037
Other languages
English (en)
Japanese (ja)
Inventor
正樹 須藤
耕史 木下
純輝 宇田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cell & Device Laboratory Inc
Original Assignee
Stem Cell & Device Laboratory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell & Device Laboratory Inc filed Critical Stem Cell & Device Laboratory Inc
Priority to JP2022501954A priority Critical patent/JPWO2021166984A1/ja
Publication of WO2021166984A1 publication Critical patent/WO2021166984A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/22—Petri dishes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues

Definitions

  • the present invention relates to a method for producing a nerve cell device containing a nerve cell having myelinated axons by co-culturing Schwann cells and a nerve cell on a fiber sheet, and a nerve cell device produced by the method. ..
  • the axons of nerve cells are covered with a myelin sheath in which the cell membranes of glial cells are spirally stacked in multiple layers.
  • Schwann cells in the peripheral nerves and oligodendrocytes in the central nerves are involved in the formation of myelin sheaths. Since nerve axons are electrically insulated by this myelin sheath, electrical signals generated by firing of nerve cells (generation of action potentials) are transmitted very quickly along the axons by saltatory conduction. ..
  • the myelin sheath also has a protective effect on nerve axons.
  • Demyelination means that the myelin sheath is damaged or shed by some mechanism, or the myelin sheath is dysplasia and the maintenance / regeneration disorder of the myelin sheath is dysplastic. It is a condition that collapses. When demyelination occurs, the transmission of nerve stimuli is extremely slow, and smooth nerve function is not maintained, resulting in various nerve dysfunctions.
  • Demyelinating diseases in which demyelinating is the basis of lesions include peripheral neuropathy such as neurosheath disease, Charcot-Marie-Tooth disease, Gillan Valley syndrome and diabetic peripheral neuropathy, as well as multiple sclerosis and neuromyelitis optica. Includes central neuropathy such as inflammation, acute disseminated neuromyelitis and Periceus-Merzbacher's disease.
  • Patent Document 1 Non-Patent.
  • ES cells embryonic stem cells
  • iPS cells induced pluripotent stem cells
  • Patent Documents 1 to 3 myelin formation can be induced by co-culturing Schwann cells and nerve cells.
  • Schwann cells derived from human stem cells are used, long-term culture is required before myelination is observed, and the efficiency of myelination cannot be said to be high.
  • Non-Patent Document 7 a method of culturing human Schwan cells together with carbon fibers suspended in a culture solution away from the culture well surface has been reported (Non-Patent Document 7).
  • Schwann cells have been shown to wrap around carbon fiber and express myelin basic protein (MBP) and myelin-related glycoprotein (MAG).
  • MBP myelin basic protein
  • MAG myelin-related glycoprotein
  • An object of the present invention is to stably culture human-derived nerve cells and Schwann cells, to mature the cells at an early stage, and to obtain a culture method having high myelin formation efficiency and the method. To provide an in vitro disease model.
  • the present inventors have found that co-culturing human-derived Schwann cells and nerve cells on a fiber sheet promotes the maturation of Schwann cells and nerve cells and improves the efficiency of myelin formation.
  • the invention was completed.
  • the object of the present invention is achieved by the following invention.
  • [1] The process of inducing the differentiation of Schwann progenitor cells into Schwann cells, and The step of co-culturing the Schwann cells with nerve cells or nerve cell spheroids on a cell scaffold, A method for manufacturing a nerve cell device, including.
  • [2] The method according to [1], wherein the step of inducing differentiation is performed on the cell scaffold.
  • the cell scaffold is a fiber sheet made of a polymer material.
  • [4] The method according to [3], wherein the fiber sheet has an oriented structure.
  • the Schwann cell derived from the pluripotent stem cell is a Schwann cell derived from a mammal.
  • the nerve cell is a primary cultured cell or a nerve cell derived from a pluripotent stem cell.
  • the primary cultured cell or a nerve cell derived from a pluripotent stem cell is a nerve cell derived from a mammal.
  • the co-culture is started by seeding the nerve cells at a density of 1 to 10 ⁇ 10 4 cells / 0.07 cm 2 with respect to the cell scaffold, according to any one of [1] to [12]. the method of. [14]
  • the nerve cell spheroid is a nerve cell spheroid prepared from 0.5 to 5 ⁇ 10 4 nerve cells, and the co-culture seeds the nerve cell spheroid at a density of 1 to 10 cells / 0.07 cm 2.
  • the culture medium used for the co-culture is a culture medium containing 5 to 20% (v / v) of the culture supernatant of IFRS1 which is a rat Schwann cell line and 0.000001 to 0.001% (w / v) of lipids [1]. ] To [14].
  • the nerve cell device according to [16] further comprising a frame that holds the periphery of the nerve cell device.
  • co-culturing human-derived neurons and Schwann cells on an oriented fiber sheet enables stable culture with less cell detachment during culture and promotes maturation of neurons. be able to. Further, according to the present invention, it is possible to prepare an in vitro disease model in which myelination is advanced in axons extending from nerve cells or nerve cell spheroids. By using the nerve cell device of the present invention, an in vitro drug screening system can be rapidly constructed, so that efficient drug evaluation becomes possible.
  • Human Schwann progenitor cells seeded on the cell scaffold were induced to differentiate into Schwann cells, and immunostaining with anti-SOX10 antibody and anti-S100B antibody was performed 16 days after the start of differentiation induction. It is a phase difference optical micrograph showing the result of co-culturing human iPS cell-derived motor neurons and Schwann cells. Rat immortalized Schwann cells or human iPS cell-derived Schwann cells were seeded into the motor nerves on the Petri dish and co-cultured. The day after seeding Schwann cells, the cells were observed with a retardation optical microscope. As a result, it was observed that Schwann cells adhered along the nerve cell axons.
  • FIG. 1 It is a photograph which shows the result of culturing the human iPS cell-derived motor neuron spheroid on the fiber sheet which is a cell scaffold.
  • the figure on the left is an optical micrograph with transmitted light.
  • the figure on the right shows the results of immunostaining with anti- ⁇ III-Tubulin antibody and nuclear staining with DAPI. From this figure, it is shown that axons extend along the fibers from the human iPS cell-derived motor nerve spheroids seeded on the fiber sheet.
  • a cell scaffold is a substrate on which cells seeded on a cell scaffold can adhere and proliferate or grow.
  • the cell scaffold preferably used in the present invention is composed of fibers made of a polymer material.
  • the cell scaffold is preferably a fiber sheet having the shape of a sheet in which fibers are accumulated.
  • the fiber sheet has an oriented structure.
  • the oriented structure means that the fibers constituting the fiber sheet are arranged along one direction, and when the angle of the one direction (orientation axis) is 0 °, 80% or more of the fibers are preferably 95%.
  • the structure is such that the above number of fibers are arranged along an angle within a range of ⁇ 5 °, preferably within a range of ⁇ 1 °.
  • the polymer material constituting the fiber may be any material that does not exhibit cytotoxicity when the cells are cultured in contact with the cells, depending on the purpose of use of the cells grown on the fiber sheet.
  • Biodegradable or non-biodegradable polymeric materials can be used.
  • the biodegradable polymer material include a copolymer of polylactic acid and polyglycolic acid (PLGA), polyglycolic acid (PGA), polybutyric acid (PLA), polyvinyl alcohol (PVA), and polyethylene glycol (PEG).
  • PLGA polylactic acid and polyglycolic acid
  • PGA polyglycolic acid
  • PLA polybutyric acid
  • PVA polyvinyl alcohol
  • PEG polyethylene glycol
  • PEVA Polyethylene vinyl acetate
  • PEO polyethylene oxide
  • non-biodegradable polymer material examples include polystyrene (PS), polysulfone (PSU), polytetrafluoroethylene (PTFE), polycarbonate (PC), polymethylmethacrylate (PMMA), polyvinyl chloride (PVC), and the like.
  • PS polystyrene
  • PSU polysulfone
  • PTFE polytetrafluoroethylene
  • PC polycarbonate
  • PMMA polymethylmethacrylate
  • PVC polyvinyl chloride
  • examples include, but are not limited to, polyethylene terephthalate (PET), polyamide (PA) and polymethylglutalimide (PMGI).
  • the fiber sheet can be produced, for example, from a solution containing a polymer material by an electrospinning method.
  • the fiber sheet having an oriented structure is not particularly limited, but for example, a rotating drum is used, and a solution containing a polymer material is sprayed from a nozzle onto the rotating surface of the drum while rotating the drum. Then, the fiber sheet can be manufactured by winding the fiber formed on the rotating drum.
  • a PTFE sheet for example, commercially available Poaflon (registered trademark, Sumitomo Electric Industries, Ltd.) can be used.
  • the solution of the polymer material may be an organic solvent that dissolves the polymer material to be used at a concentration of 10 to 30% (w / v) at room temperature, for example, 1,1,1,3,3,3.
  • HFIP -Hexafluoro-2-propanol
  • DMF N, N-dimethylformamide
  • the average diameter of the orthogonal cross sections of the fibers constituting the fiber sheet is not particularly limited, but is, for example, 1 to 7 ⁇ m, preferably 2 to 6 ⁇ m, and more preferably 3 to 5 ⁇ m.
  • the distance between the core wires of adjacent fibers is the pitch. If the pitch is too large, the cells may not be retained and may fall out when seeded. On the other hand, if the pitch is too small, the cells cannot extend into the fiber sheet, and it becomes difficult to form a three-dimensional structure.
  • the pitch of the fiber sheet used in the present invention is 6 ⁇ m to 60 ⁇ m, preferably 6 ⁇ m to 50 ⁇ m, and more preferably 6 ⁇ m to 30 ⁇ m.
  • the porosity of the fibers constituting the fiber sheet may vary depending on the polymer material used.
  • the porosity is not particularly limited, but is, for example, 10 to 60%, preferably 15 to 50%, more preferably 20 to 40%, and even more preferably 30% to 40%.
  • the porosity is the ratio of the area where fibers do not exist to a certain area of the fiber sheet plane in the fiber sheet which is one layer in the direction perpendicular to the fiber sheet plane.
  • the fiber sheet used in the present invention is composed of two or more fiber sheet layers (laminated or multilayer) even if it is composed of one fiber sheet layer (single layer) in the direction perpendicular to the fiber sheet plane. , For example, 2 layers, 3 layers, 4 layers, 5 layers, 6 layers, etc.).
  • the upper and lower fiber sheets are in contact with each other.
  • the orientation axes of the upper and lower fiber sheets intersect at 5 ° to 25 °, preferably 10 ° to 20 °, and more preferably 13 ° to 17 °.
  • the thickness of the fiber sheet (single layer) is, for example, 1 to 40 ⁇ m, preferably 5 to 35 ⁇ m, and more preferably 10 to 30 ⁇ m.
  • the fiber sheet used in the present invention is an extracellular matrix such as polylysine, polyornithine, laminin, fibronectin, Matrigel® or Geltrex® to promote adhesion, elongation and proliferation of seeded cells. It may be coated with protein or polyethyleneimine, which is a cationic water-soluble polymer. The coating can be performed by immersing the fiber sheet in a solution in which the extracellular matrix protein or polyethyleneimine is dissolved in physiological saline, phosphate buffered saline, cell culture solution or the like.
  • Nerve cells also called neurons
  • glial cells that differentiate from each progenitor cell of the nervous system form functional nervous tissue through the interaction of nerve cells with glial cells.
  • Schwann cells are the major glial cells in the peripheral nerves.
  • Schwann cells support the metabolic activity of nerve cells and play a role as myelin-forming cells.
  • Schwann cells are cells that differentiate from stem cells through Schwann progenitor cells and then immature Schwann cells.
  • the method of the present invention is a step of seeding and culturing Schwann precursor cells on a cell culture vessel such as Petridish or a multi-well plate or a cell scaffold in which fibers produced by using the polymer material are accumulated, and the above-mentioned.
  • the step of inducing the differentiation of Schwann precursor cells into Schwann cells is included. Since Schwann progenitor cells have the ability to differentiate into mature Schwann cells, they can be differentiated into Schwann cells by adherent culture on a cell culture vessel or the cell scaffold.
  • the Schwann progenitor cells are positive for the transcription factor SOX10, which is an undifferentiated Schwann cell marker, and OCT6, which is a mature Schwann cell marker, is positive for the subsequent induction of differentiation. Becomes positive. These markers can be used to identify Schwann progenitor cells, mature Schwann cells, or Schwann cell populations involved in myelination.
  • the Schwann progenitor cells are preferably cells induced to differentiate from pluripotent stem cells.
  • the pluripotent stem cells for example, ES cells and iPS cells can be used, but iPS cells are more preferable.
  • the cells for reprogramming into iPS cells cells derived from mammals such as mice or rats which are rodents, or monkeys or humans which are primates are preferable, and cells derived from humans are particularly preferable.
  • Patient-derived cells can also be used. By using patient-derived cells, it becomes possible to manufacture a nerve cell device that reflects the disease state.
  • Patient diseases include CMT subtypes such as Charcot-Marie-Tooth disease (CMT) or CMT type 1. Since Schwann progenitor cells can be cryopreserved, the cryopreserved Schwann cells can be thawed and used when producing the nerve cell device of the present invention.
  • CMT Charcot-Marie-Tooth disease
  • Examples of the culture medium used in the step of inducing the differentiation of Schwann progenitor cells into Schwann cells include DMEM (Dulbecco's Modified Eagle Medium) and MEM / Ham F-12, and the induction of differentiation of Schwann progenitor cells into Schwann cells. Is not limited as long as is possible. It is preferable that serum and / or cell growth factor is added to the culture medium. Examples of serum include fetal bovine serum (FBS), neonatal bovine serum, bovine serum albumin, goat serum, rabbit serum, mouse serum, monkey serum, human serum, etc., and the induction of differentiation of Schwann precursor cells into Schwann cells is performed. It is not limited as long as it is possible.
  • FBS fetal bovine serum
  • bovine serum albumin goat serum
  • rabbit serum rabbit serum
  • mouse serum monkey serum
  • human serum etc.
  • the induction of differentiation of Schwann precursor cells into Schwann cells is performed. It is not limited as long as it is possible.
  • cell growth factors examples include PDGF (platelet-derived growth factor), EGF (Epidermal Growth Factor), and FGF (Fibroblast growth factor). It is not limited as long as it is possible to induce the differentiation of Schwan precursor cells into Schwan cells. In addition, other well-known substances or antibiotics, or combinations thereof, may be added to the culture medium in order to maintain the cultured cells and promote the induction of differentiation.
  • the method of the present invention includes a step of inducing differentiation of the Schwann progenitor cells into Schwann cells, then seeding nerve cells or nerve cell spheroids on the cell scaffold and co-culturing with the Schwann cells.
  • Nerve cells are also called neurons and can be classified according to the difference in neurotransmitters produced by nerve cells.
  • Neurotransmitters produced by nerve cells used in the method of the present invention include monoamines such as dopamine, noradrenaline, adrenaline, serotonin and histamine, non-peptide neurotransmitters such as acetylcholine, ⁇ -aminobutyric acid and glutamate, and , Adrenocorticotropic hormone (ACTH), ⁇ -endorphin, ⁇ -endorphin, ⁇ -endorphin and vasopressin and other peptide neurotransmitters.
  • monoamines such as dopamine, noradrenaline, adrenaline, serotonin and histamine
  • non-peptide neurotransmitters such as acetylcholine, ⁇ -aminobutyric acid and glutamate
  • Adrenocorticotropic hormone (ACTH) Adrenocorticotropic hormone
  • ⁇ -endorphin, ⁇ -endorphin, ⁇ -endorphin and vasopressin and other peptide neurotransmitters.
  • neurons using glutamate, acetylcholine, ⁇ -aminobutyric acid, dopamine and histamine as neurotransmitters are classified into glutamate-operated neurons, cholinergic neurons, ⁇ -aminobutyric acid-operated neurons, dopaminergic neurons and histamine-actuated neurons, respectively. It is called a sex neuron.
  • nerve cells used in the present invention include primary cultured cells. Since primary cultured cells retain many cell functions that are inherent in the living body, they are important as a system for evaluating the effects of drugs and the like in the living body.
  • the primary cultured cells neurons of a mammal such as a rodent mouse or rat, or a primate monkey or human central nervous system and peripheral nervous system can be used.
  • the animal dissection method, tissue collection method, nerve separation / isolation method, nerve cell culture medium, culture conditions, etc. are known depending on the type of cells to be cultured. You can choose from the methods.
  • primary cultured divine cell products for example, rat brain nerve cells manufactured by Lonza (Switzerland) and human brain nerve cells manufactured by ScienCell Research Laboratories (USA) can be used.
  • a nerve cell induced to differentiate from a pluripotent stem cell can be mentioned.
  • the pluripotent stem cells for example, embryonic stem cells (ES cells) and iPS cells can be used, but iPS cells are preferable.
  • the cells for reprogramming into iPS cells cells derived from mammals such as rodent mice or rats, or primates monkeys or humans can be used, but human-derived cells can be used. Is preferred, and patient-derived cells are particularly preferred. By using patient-derived cells, it becomes possible to manufacture a nerve cell device that reflects the disease state.
  • Patient diseases include CMT subtypes such as Charcot-Marie-Tooth disease (CMT) or CMT type 1.
  • Pluripotent stem cells can obtain various types of nerve cells by inducing differentiation using a known method for inducing nerve differentiation.
  • nerve cells can be obtained by a differentiation induction method using a small molecule compound described in the literature (Honda M, et al. Biochem Biophys Res Communi. 2016; 469: 587-592).
  • commercially available pluripotent stem cell-derived neural cell products such as iCell neurons from Cellular Dynamics International (USA), various neural stem cells from Axol Bioscience (UK), and various neural cell precursors from BrainXell (USA). Cells and XCL-1 neurons from XCell Science (USA) can also be used. These commercially available nerve cells can be cultured using the attached culture medium.
  • nerve cell spheroids can be used.
  • a nerve cell spheroid is a three-dimensional structure (cell mass) formed by adhesion and aggregation of nerve cells.
  • a method for producing a nerve cell spheroid for example, a certain number of nerve cells are added to each well of a microwell having a cell non-adhesive surface and cultured to adhere the nerve cells to each other in the microwell. The method of producing is exemplified.
  • the number of nerve cells added to each well of the microwell is preferably 0.5 to 5 ⁇ 10 4.
  • a method of rotating a cell culture chamber containing nerve cells and a culture solution and bringing suspended nerve cells into contact with each other in the chamber is exemplified.
  • the method is not limited to these methods as long as the number and size of the obtained neuronal spheroids are relatively uniform.
  • peripheral blood-derived mononuclear cells are preferable as a source of cells for reprogramming into iPS cells because of their low invasiveness. Not limited to.
  • Other preferable sources of collection include body tissues such as skin containing fibroblasts.
  • a nerve cell or a nerve cell spheroid is further seeded on the cell scaffold on which the Schwann cell differentiated from the Schwann progenitor cell grows, and co-cultured with the Schwann cell.
  • the nerve cells or nerve cell spheroids seeded on the cell scaffold are cultured for a certain period of time, axons are extended from the respective cells and spheroids, and then the Schwann cells are seeded and co-cultured.
  • the cells or the cell scaffold on which the nerve cell spheroids grow at a density of 0.5 to 3 ⁇ 10 4 cells / 0.07 cm 2. These cell seeding densities may be seeded at a density lower than the seeding density or higher than the seeding density, depending on the growth situation of each cell.
  • the cell scaffold on which Schwann cells grow at a density of 1 to 10 spheroids / 0.07 cm 2. The number of spheroids added on the cell scaffold can be adjusted so that all of the added spheroids are in contact with the grown and extended Schwann cells on the cell scaffold.
  • the culture medium used in the step of co-culturing the Schwann cell and the nerve cell or the nerve cell spheroid is DMEM culture solution, DMEM / Ham F-12 equal volume mixed culture solution, 1 ⁇ Neurobasal (registered trademark, Gibco) and the like.
  • DMEM culture solution DMEM / Ham F-12 equal volume mixed culture solution
  • 1 ⁇ Neurobasal registered trademark, Gibco
  • serum and / or cell growth factor is added to the culture medium.
  • serum include fetal bovine serum (FBS), neonatal bovine serum, bovine serum albumin, goat serum, rabbit serum, mouse serum, monkey serum, human serum, etc., and axonal formation and myelin formation of nerve cells are possible. If so, there is no limit.
  • Cell growth factors include NGF (nerve growth factor), BDNF (brain-derived neurotrophic factor), GDNF (glial cell-derived neurotrophic factor), and NT.
  • NGF nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • GDNF glial cell-derived neurotrophic factor
  • NT neurotrophic factor
  • Examples thereof include -3 (neurotrophin-3; neurotrophin-3), NRG-1 (neuregulin-1; neurotrophin-1), PDGF, EGF, FGF, etc. Unrestricted if possible.
  • other well-known substances or antibiotics, or combinations thereof may be added to the culture medium to promote axonal formation and myelination of nerve cells.
  • the culture solution (IFRS1 culture supernatant) after culturing IFRS1 which is a rat Schwann cell line may be added to the culture solution used in the co-culture step at a concentration of 1 to 20% (v / v).
  • IFRS1 is an immortalized cell line established from the dorsal root ganglion and peripheral nerve tissue of mature Fisher344 rats.
  • IFRS1 can be purchased from Cosmo Bio, and can be cultured using a culture medium for IFRS1 (Cosmo Bio) using DMEM as a basal medium. It is preferable that lipid is further added to the culture solution used in the co-culturing step.
  • the lipid examples include, but are not limited to, linolenic acid, oleic acid, palmitic acid, cholesterol, phosphatidylcholine, etc., as long as they can form axons and myelin in nerve cells.
  • the lipid may be added alone or as a lipid concentrate consisting of a mixture of the lipids.
  • examples of the lipid concentrate include, but are not limited to, a lipid concentrate (Gibco).
  • the concentration of the lipid to be added is preferably 0.000001 to 0.001% (w / v), more preferably 0.000003 to 0.0003% (w / v).
  • the nerve cell By co-culturing the Schwann cell with a nerve cell or a nerve cell spheroid, the nerve cell in which the cell forms a three-dimensional structure on the fiber sheet which is a cell scaffold or laminated and / or in the fiber sheet. You get the device.
  • Forming a three-dimensional structure means a state in which Schwann cells and nerve cells adhere along the fibers constituting the fiber sheet and grow on one or both sides of the fiber sheet and in the fiber sheet.
  • the nerve cell device produced by the method of the present invention has a neural network in which myelinated nerve cells form a three-dimensional structure on and / or in the fiber sheet. Such neuronal devices are preferably stored in contact with cell culture medium in order to keep the cells alive.
  • a Petri dish or plate comprising the neuronal device of the invention is provided.
  • the nerve cell device of the present invention can form a fiber sheet by fixing or holding the periphery of the fiber sheet constituting the device with a frame.
  • a commercially available biocompatible adhesive such as silicone one-component condensation type RVT rubber (Shin-Etsu Chemical Co., Ltd., Catalog No. KE-45) can be used, but cells can be used.
  • the adhesive is not particularly limited as long as it does not affect the culture.
  • the material of the frame examples include polydimethylsiloxane (PDMS), polystyrene (PS), polycarbonate (PC), stainless steel, and the like, but the material is not limited to these as long as it does not affect cell culture.
  • the thickness of the frame is not particularly limited, but is 0.1 to 4 mm, preferably 0.25 to 3 mm, and more preferably 0.5 to 2 mm.
  • the shape of the frame can be changed depending on the purpose of use, but it is circular or polygonal, and it is preferable that the length and width are 2 mm ⁇ 2 mm to 15 mm ⁇ 15 mm, respectively.
  • the nerve cell device of the present invention is a petri dish for cell culture having a diameter of 35 mm, 60 mm, 100 mm, etc., or a mulch having a plurality of wells such as 6 wells, 12 wells, 24 wells, 48 wells, and 96 wells. It can be directly attached or placed in at least one of the wells contained in the well plate. The same applies to a nerve cell device having a fiber sheet in which the periphery of the fiber sheet is fixed or held by the frame.
  • PLGA (SIGMA P1941) was dissolved in HFIP (Wako Pure Chemical Industries, Ltd. 089-04233) at room temperature to prepare a 20% (w / v) solution. This solution was filled in a syringe (Norm-Ject Syringes 5 mL volume, Osaka Chemical) and then placed in a nanofiber electrospinning device NANON-03 (Mech Co., Ltd.) equipped with a 22 G flat-edged needle. Next, a PLGA fiber sheet was prepared on the drum collector under the conditions of a voltage of 20 kV, an injection flow rate of 1 mL / h, and a drum rotation speed of 750 rpm.
  • PS Frequency Division Multiple Access (Fluka) was dissolved in DMF (Wako Pure Chemical Industries, Ltd.) at room temperature to prepare a 30% (w / v) solution.
  • This solution was filled in a syringe (Norm-Ject Syringes 5 mL volume, Osaka Chemical) and then placed in a nanofiber electrospinning device NANON-03 (Mech Co., Ltd.) equipped with a needle with a flat cutting edge of 25 G.
  • a PS fiber sheet was prepared on the drum collector under the conditions of a voltage of 10 kV, an injection flow rate of 1.5 mL / h, and a drum rotation speed of 2000 rpm.
  • Schwann progenitor cells were prepared by inducing differentiation of human-derived iPS cells according to known conditions.
  • SOX10 which is a Schwann cell-specific transcription factor, was expressed in 86% or more of the cells (Fig. 1).
  • These Schwann progenitor cells were seeded on an oriented PS fiber sheet and cultured in a 5% CO 2 environment at 37 ° C. for about 10 days using a differentiation-inducing culture medium to differentiate into Schwann cells.
  • low glucose DMEM (Sigma, D5546) was used as the basal culture medium, and 1% FBS and 2 mM L-glutamine were added to the culture medium.
  • 200 ng / mL NRG1 (Peprotec, 100-03) and 100 nM all-trans retinoic acid (Peprotec, 100-03) and 100 nM all transretinoic acid (200 ng / mL NRG1 (Peprotec, 100-03)) Sigma, R2625)
  • 10 ng / mL PDGF-BB Gibco, PHG0044
  • 4 ⁇ M forskolin (Sigma, F6886) were added and 200 ng / mL NRG1 and 10 ng / mL PDGF were added on days 5-6.
  • -BB was added, and after the 7th day, the cells were cultured using a culture solution containing 200 ng / mL NRG1. On days 10 and 13, half of the culture was replaced with fresh culture. On the 16th day, immunostaining of Schwann cell markers SOX10 and S100B was performed, and almost all cells were positive (Fig. 2).
  • the culture medium for co-culture uses Neurobasal (registered trademark, Thermo Fisher) as the basal culture solution, 2% B-27 (registered trademark, Thermo Fisher), 20 ng / mL NRG1, 10 ng / mL BDNF, 10 ng /. mL GDNF, 0.1 mM mercaptoethanol, 0.5 ⁇ M forskolin, 1% penicillin-streptomycin and 0.3% growth factor reduced Matrigel (Corning) were added. The day after seeding the rat or human Schwann cells, observation with a phase-difference optical microscope confirmed that each Schwann cell was engrafted along the nerve cell axon (Fig. 3).
  • Rat immortalized Schwann cells (IFRS1) were seeded at a density of 0.5 to 5 ⁇ 10 4 cells / 0.07 cm 2 into human-derived motor neurons cultured on an oriented PS fiber sheet, and a co-culture medium was used. The cells were cultured at 37 ° C in a 5% CO 2 environment.
  • the culture medium for co-culture uses Neurobasal (registered trademark, Thermo Fisher) as the basal culture solution, and is 2% B-27 (registered trademark, Thermo Fisher), 20 ng / mL NRG1, 10 ng / mL BDNF, 10 ng /.
  • GDNF 0.1 mM mercaptoethanol, 0.5 ⁇ M forskolin, 1% penicillin-streptomycin were added.
  • 50 ⁇ g / mL ascorbic acid is added to the co-culture solution after the 6th day, with the sowing date of nerve cells (co-culture start date) as the 0th day, and myelinated culture is performed. Used as a liquid. From the 6th day onward, half of the culture broth was replaced with fresh culture broth every 2 to 3 days.
  • immunostaining of the obtained nerve cell device was performed 4 to 6 weeks after the start date of co-culture, expression of myelin formation-related proteins MBP and CASPR was observed at multiple sites (Fig. 4). In addition, almost no cell detachment from the cell scaffold was observed. Therefore, it is shown that the nerve cell device produced by the method of the present invention is useful as an in vitro neural tissue model.
  • Human-derived Schwann cells differentiated on an oriented PS fiber sheet, and primary cultured neurons derived from the rat spinal posterior ganglion, which are peripheral sensory neurons, or neurons derived from human motor / sensory neurons, 1 to 5
  • the cells were seeded at a density of ⁇ 10 4 cells / 0.07 cm 2 , and cultured at 37 ° C. in a 5% CO 2 environment using a co-cultivation culture medium.
  • the culture medium for co-culture uses Neurobasal (registered trademark, Thermo Fisher) as the basal culture solution, and is 2% B-27 (registered trademark, Thermo Fisher), 20 ng / mL NRG1, 10 ng / mL BDNF, 10 ng /. mL GDNF, 0.1 mM mercaptoethanol, 0.5 ⁇ M forskolin, 1% penicillin-streptomycin, culture supernatant of 5-10% (v / v) rat Schwann cell line IFRS1 and 0.00001% (w / v) lipid concentrate
  • the culture solution was prepared by adding (Gibco).
  • nerve cell device produced by the method of the present invention 50 ⁇ g / mL ascorbic acid was added to the co-culture solution on the 0th day after the seeding date of nerve cells (co-culture start date) to promote myelin formation. It is shown that in the nerve cell device produced by the method of the present invention, aggregation and cell detachment of nerve cell axons did not occur even one month after the start of co-culture (Fig. 5). Therefore, it is shown that the nerve cell device produced by the method of the present invention is useful as an in vitro neural tissue model.
  • Nerve cell spheroids were prepared by adding 2 ⁇ 10 4 motile / sensory nerve cells induced to differentiate from human iPS cells to each well of the microwell and culturing them.
  • the nerve cell spheroids were seeded on a cell scaffold, which is a PS fiber sheet coated with polylysine and laminin, at a density of 1 to 2 cells / 0.07 cm 2 , and a co-culture medium was used in a 5% CO 2 environment. , 37 ° C.
  • the culture medium for co-culture uses Neurobasal (registered trademark, Thermo Fisher) as the basal culture solution, and is 2% B-27 (registered trademark, Thermo Fisher), 20 ng / mL NRG1, 10 ng / mL BDNF, 10 ng /. mL GDNF, 0.1 mM mercaptoethanol, 0.5 ⁇ M forskolin, 1% penicillin-streptomycin, culture supernatant of 5-10% (v / v) rat Schwann cell line IFRS1 and 0.00001% (w / v) lipid concentrate
  • the culture solution was prepared by adding (Gibco).

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Sustainable Development (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne : un procédé de fabrication d'un système de cellules nerveuses qui comprend des cellules nerveuses ayant des axones hautement myélinisés, par co-culture de cellules de Schwann et de cellules nerveuses sur une feuille de fibres; et un système de cellules nerveuses fabriqué par ledit procédé.
PCT/JP2021/006037 2020-02-20 2021-02-18 Procédé de fabrication d'un systèmes de cellules nerveuses comprenant des cellules nerveuses myélinisées Ceased WO2021166984A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022501954A JPWO2021166984A1 (fr) 2020-02-20 2021-02-18

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020026698 2020-02-20
JP2020-026698 2020-02-20

Publications (1)

Publication Number Publication Date
WO2021166984A1 true WO2021166984A1 (fr) 2021-08-26

Family

ID=77392160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/006037 Ceased WO2021166984A1 (fr) 2020-02-20 2021-02-18 Procédé de fabrication d'un systèmes de cellules nerveuses comprenant des cellules nerveuses myélinisées

Country Status (2)

Country Link
JP (1) JPWO2021166984A1 (fr)
WO (1) WO2021166984A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535265A (ja) * 2016-11-14 2019-12-12 メモリアル スローン ケタリング キャンサー センター 幹細胞由来シュワン細胞
WO2020013269A1 (fr) * 2018-07-12 2020-01-16 学校法人東北工業大学 Procédé de maturation fonctionnelle de neurones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535265A (ja) * 2016-11-14 2019-12-12 メモリアル スローン ケタリング キャンサー センター 幹細胞由来シュワン細胞
WO2020013269A1 (fr) * 2018-07-12 2020-01-16 学校法人東北工業大学 Procédé de maturation fonctionnelle de neurones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Notice of started joint research with Kyoto Prefectural University of Medicine -Development of Charcot-Marie-Tooth disease model using patient- derived iPS cells", IPS PRESS RELEASE, 16 December 2019 (2019-12-16), pages 1 - 4, XP055849790, Retrieved from the Internet <URL:https://scad-kyoto.com/PDF/SCAD%20Press%20Release%2020191216%20kpu-m.pdf> [retrieved on 20210421] *

Also Published As

Publication number Publication date
JPWO2021166984A1 (fr) 2021-08-26

Similar Documents

Publication Publication Date Title
Amores de Sousa et al. Functionalization of electrospun nanofibers and fiber alignment enhance neural stem cell proliferation and neuronal differentiation
Ylä‐Outinen et al. Three‐dimensional growth matrix for human embryonic stem cell‐derived neuronal cells
Xue et al. Promoting cell migration and neurite extension along uniaxially aligned nanofibers with biomacromolecular particles in a density gradient
Xiang et al. A novel Bruch's membrane-mimetic electrospun substrate scaffold for human retinal pigment epithelium cells
Xue et al. Differentiation of bone marrow stem cells into Schwann cells for the promotion of neurite outgrowth on electrospun fibers
Gerardo-Nava et al. Human neural cell interactions with orientated electrospun nanofibers in vitro
Kabiri et al. Neural differentiation of mouse embryonic stem cells on conductive nanofiber scaffolds
JP2020504625A (ja) 細胞療法および創薬のための３ｄ血管化ヒト眼組織
Kabiri et al. Cytocompatibility of a conductive nanofibrous carbon nanotube/poly (L-Lactic acid) composite scaffold intended for nerve tissue engineering
JP2007510820A (ja) ナノフィブリル構造体ならびに細胞および組織培養を含めた応用例
US11629321B2 (en) Scaffold for cell culture or tissue engineering
WO2007012050A2 (fr) Structures nanofibrilaires revetues de polymere et procedes de maintenance et de differenciation cellulaire
Yari et al. The role of biodegradable engineered random polycaprolactone nanofiber scaffolds seeded with nestin-positive hair follicle stem cells for tissue engineering
US11543404B2 (en) Nerve cell device and method for evaluating neural activity
Hodde et al. Characterisation of cell–substrate interactions between Schwann cells and three‐dimensional fibrin hydrogels containing orientated nanofibre topographical cues
CN103351484A (zh) 一种微图案化水凝胶涂层及其制备方法与用途
Morelli et al. Microtube array membrane bioreactor promotes neuronal differentiation and orientation
Revkova et al. Spidroin silk fibers with bioactive motifs of extracellular proteins for neural tissue engineering
Ortega et al. Characterisation and evaluation of the impact of microfabricated pockets on the performance of limbal epithelial stem cells in biodegradable PLGA membranes for corneal regeneration
Yucel et al. Tissue engineered, guided nerve tube consisting of aligned neural stem cells and astrocytes
Ghoroghi et al. Evaluation of the effect of NT-3 and biodegradable poly-L-lactic acid nanofiber scaffolds on differentiation of rat hair follicle stem cells into neural cells in vitro
Yang et al. Carbon nanotube polymer scaffolds as a conductive alternative for the construction of retinal sheet tissue
Pavia et al. A 3D-scaffold of PLLA induces the morphological differentiation and migration of primary astrocytes and promotes the production of extracellular vesicles
Iwoń et al. Maturation of human cardiomyocytes derived from induced pluripotent stem cells (iPSC-CMs) on polycaprolactone and polyurethane nanofibrous mats
US20220364049A1 (en) Composition and methods for culturing retinal progenitor cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21757159

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022501954

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21757159

Country of ref document: EP

Kind code of ref document: A1